CYCN - Cyclerion Therapeutics, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Currency in USD

Valuation measures4

Market cap (intra-day) 8.32M
Enterprise value -45.64M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/sales (ttm)27.98
Price/book (mrq)0.80
Enterprise value/revenue -633.88
Enterprise value/EBITDA 1.19

Trading information

Stock price history

Beta (5Y monthly) 1.93
52-week change 3-66.33%
S&P500 52-week change 33.90%
52-week high 325.0000
52-week low 33.6400
50-day moving average 36.0355
200-day moving average 311.6159

Share statistics

Avg vol (3-month) 335.38k
Avg vol (10-day) 326.76k
Shares outstanding 52.4M
Implied shares outstanding 6N/A
Float 81.27M
% held by insiders 1N/A
% held by institutions 1N/A
Shares short (14 May 2023) 413.54k
Short ratio (14 May 2023) 41.55
Short % of float (14 May 2023) 40.81%
Short % of shares outstanding (14 May 2023) 40.62%
Shares short (prior month 13 Apr 2023) 412.28k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:20
Last split date 315 May 2023

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)30 Mar 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-4,204.60%

Management effectiveness

Return on assets (ttm)-82.85%
Return on equity (ttm)-185.82%

Income statement

Revenue (ttm)914k
Revenue per share (ttm)0.42
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -38.4M
Net income avi to common (ttm)-38.05M
Diluted EPS (ttm)-17.4400
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)7.17M
Total cash per share (mrq)3.29
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)1.11
Book value per share (mrq)1.80

Cash flow statement

Operating cash flow (ttm)-33.99M
Levered free cash flow (ttm)-20.51M